Renal cancer: Molecular mechanisms and newer therapeutic options

S. Ananth Karumanchi, Jaime R Merchan, Vikas P. Sukhatme

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Renal cell carcinomas account for 80-85% of all primary renal neoplasms. Recent identification of VHL, c-met and TSC as candidate genes mutated in various types of renal carcinomas has greatly enhanced our understanding of the pathogenesis of renal carcinomas and has provided novel therapeutic options for patients with renal cancer. Furthermore, developments in angiogenesis and in tumor immunology have given us additional treatment modalities for cancer patients, especially those with renal cancer. This review highlights the genetic abnormalities seen in renal cell carcinomas and reviews current and future therapeutic options.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume11
Issue number1
DOIs
StatePublished - Jan 21 2002
Externally publishedYes

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Carcinoma
Kidney
Allergy and Immunology
Neoplasms
Therapeutics
Genes

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Renal cancer : Molecular mechanisms and newer therapeutic options. / Karumanchi, S. Ananth; Merchan, Jaime R; Sukhatme, Vikas P.

In: Current Opinion in Nephrology and Hypertension, Vol. 11, No. 1, 21.01.2002, p. 37-42.

Research output: Contribution to journalArticle

@article{78e9155ab6344398a6aaff4d1bff3896,
title = "Renal cancer: Molecular mechanisms and newer therapeutic options",
abstract = "Renal cell carcinomas account for 80-85{\%} of all primary renal neoplasms. Recent identification of VHL, c-met and TSC as candidate genes mutated in various types of renal carcinomas has greatly enhanced our understanding of the pathogenesis of renal carcinomas and has provided novel therapeutic options for patients with renal cancer. Furthermore, developments in angiogenesis and in tumor immunology have given us additional treatment modalities for cancer patients, especially those with renal cancer. This review highlights the genetic abnormalities seen in renal cell carcinomas and reviews current and future therapeutic options.",
author = "Karumanchi, {S. Ananth} and Merchan, {Jaime R} and Sukhatme, {Vikas P.}",
year = "2002",
month = "1",
day = "21",
doi = "10.1097/00041552-200201000-00006",
language = "English",
volume = "11",
pages = "37--42",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Renal cancer

T2 - Molecular mechanisms and newer therapeutic options

AU - Karumanchi, S. Ananth

AU - Merchan, Jaime R

AU - Sukhatme, Vikas P.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - Renal cell carcinomas account for 80-85% of all primary renal neoplasms. Recent identification of VHL, c-met and TSC as candidate genes mutated in various types of renal carcinomas has greatly enhanced our understanding of the pathogenesis of renal carcinomas and has provided novel therapeutic options for patients with renal cancer. Furthermore, developments in angiogenesis and in tumor immunology have given us additional treatment modalities for cancer patients, especially those with renal cancer. This review highlights the genetic abnormalities seen in renal cell carcinomas and reviews current and future therapeutic options.

AB - Renal cell carcinomas account for 80-85% of all primary renal neoplasms. Recent identification of VHL, c-met and TSC as candidate genes mutated in various types of renal carcinomas has greatly enhanced our understanding of the pathogenesis of renal carcinomas and has provided novel therapeutic options for patients with renal cancer. Furthermore, developments in angiogenesis and in tumor immunology have given us additional treatment modalities for cancer patients, especially those with renal cancer. This review highlights the genetic abnormalities seen in renal cell carcinomas and reviews current and future therapeutic options.

UR - http://www.scopus.com/inward/record.url?scp=0036140913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036140913&partnerID=8YFLogxK

U2 - 10.1097/00041552-200201000-00006

DO - 10.1097/00041552-200201000-00006

M3 - Article

C2 - 11753085

AN - SCOPUS:0036140913

VL - 11

SP - 37

EP - 42

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 1

ER -